Health ❯ Healthcare

Autoimmune Diseases

Lupus Rheumatoid Arthritis Dermatomyositis Research Multiple Sclerosis Systemic Lupus Erythematosus B Cell-Mediated Autoimmune Diseases Stiff-Person Syndrome Crohn's Disease T-regulatory Cells Kidney Diseases Eye Inflammation Drug Development Neurologic Syndromes T Cell Reactivity Immunoglobulin G4-Related Disease Type 1 Diabetes Sjögren's Disease Psoriasis Vitiligo Immune Thrombocytopenia Chronic Illness Inflammation Stiff Person Syndrome Hashimoto's Disease Therapeutic Approaches Rheumatology Neurological Disorders Treatment

FDA Grants Breakthrough Therapy Designation to Biogen’s Litifilimab for Cutaneous Lupus

The status reflects Phase 2 evidence of reduced skin disease activity in patients with cutaneous lupus erythematosus.

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

FDA Grants Priority Review to Vera's Atacicept for IgA Nephropathy

Zenas' Obexelimab Meets Phase 3 Goals in IgG4-Related Disease With 56% Flare Risk Cut

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Kyverna CAR-T Delivers Positive Phase 2 Topline in Stiff Person Syndrome as Shares Jump

Ianalumab Plus Eltrombopag Extends Disease Control in Phase 3 ITP Study Published in NEJM

Study Pinpoints GPR25 as Switch for Tissue-Resident Memory T Cell Formation

Off-Grid Trip Ends With Nobel Call for Immunologist Fred Ramsdell

Baricitinib's Type 1 Diabetes Gains Fade After Stopping in Two-Year Follow-Up

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

Kriya Nets $320 Million Series D as Odyssey Raises $213 Million and Amgen Retools Research Leadership

Nektar Therapeutics’ Rezpegaldesleukin Trial Success Sends Shares Up 150%

CAR T-Cell Therapy Yields Lasting Remission in Chronic Inflammatory Demyelinating Polyneuropathy

New Study Reveals Unintended Consequences of Fecal Microbiota Transplants